original ) (raw )New 2-Aryloxy-3-phenyl-propanoic Acids As Peroxisome Proliferator-Activated Receptors α/γ Dual Agonists with Improved Potency and Reduced Adverse Effects on …
Antonio Lavecchia
Journal of medicinal …, 2009
View PDFchevron_right
Design and Synthesis of N -[(4-Methoxyphenoxy)carbonyl]- N -[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities
Rajasree Golla , Ramakrishna Seethala
Journal of Medicinal Chemistry, 2005
View PDFchevron_right
New 2-Aryloxy-3-phenyl-propanoic Acids As Peroxisome Proliferator-Activated Receptors α/γ Dual Agonists with Improved Potency and Reduced Adverse Effects on Skeletal Muscle Function
Fernando Mazza
Journal of Medicinal Chemistry, 2009
View PDFchevron_right
Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice
Min Hi Park
PloS one, 2013
View PDFchevron_right
A New Class of Peroxisome Proliferator-activated Receptor Agonists with a Novel Binding Epitope Shows Antidiabetic Effects
Timothy Phillips
Journal of Biological Chemistry, 2004
View PDFchevron_right
Novel Tricyclic-α-alkyloxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity
Helle Wöldike
Journal of Medicinal Chemistry, 2002
View PDFchevron_right
[4-(2H-1,2,3-Benzotriazol-2-yl)phenoxy]alkanoic Acids as Agonists of Peroxisome Proliferator-Activated Receptors (PPARs)
Jean-Charles Fruchart
Chemistry & Biodiversity, 2006
View PDFchevron_right
Synthesis and Biological Evaluation of Some Novel PPAR-γ agonists for the Management of Type II Diabetes
Sumeet Prachand
2013
View PDFchevron_right
New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression
Antonio Lavecchia
View PDFchevron_right
A Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with a Unique in Vitro Profile and Potent Glucose and Lipid Effects in Rodent Models of Type 2 Diabetes and Dyslipidemia
Isabel Rojo
Molecular Endocrinology, 2005
View PDFchevron_right
Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator–activated receptor α agonist
Mary Demarest
Metabolism-clinical and Experimental, 2008
View PDFchevron_right
In-silico Analysis of Phenyl Propanoic Acid Derivatives to Design Potent Peroxisome Proliferator-activated Receptor (PPAR) Dual Agonists for Type 2 Diabetes mellitus Therapy
Usha Chouhan
Oriental Journal of Chemistry, 2018
View PDFchevron_right
A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: Design and synthesis of benzylpyrazole acylsulfonamides
Junichi Sakamoto
Bioorganic & Medicinal Chemistry, 2012
View PDFchevron_right
Discovery of novel dual functional agent as PPARγ agonist and 11β-HSD1 inhibitor for the treatment of diabetes
Min Chen
View PDFchevron_right
A New Selective Peroxisome Proliferator-Activated Receptor γ Antagonist with Antiobesity and Antidiabetic Activity
Walter Wahli
Molecular Endocrinology, 2002
View PDFchevron_right
Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome
W. Li
Expert opinion on therapeutic targets, 2017
View PDFchevron_right
Design and synthesis of non-TZD peroxisome proliferator-activated receptor γ (PPARγ) modulator
Amrutha Nair
Medicinal Chemistry Research, 2014
View PDFchevron_right
Design and synthesis of a novel class of dual PPARγ/δ agonists
Eric Lamar
Bioorganic & Medicinal Chemistry Letters, 2007
View PDFchevron_right
P633H, a novel dual agonist at peroxisome proliferator-activated receptors α and γ, with different anti-diabetic effects in db/db and KK-A y mice
Lili Wang
British Journal of Pharmacology, 2009
View PDFchevron_right
Peroxisome Proliferator-Activated Receptors as Superior Targets for Treating Diabetic Disease, Design Strategies - Review Article
Ihab Almasri
Turkish Journal of Pharmaceutical Sciences
View PDFchevron_right
Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR) α-selective agonists
Hiroyuki Miyachi
Bioorganic & Medicinal Chemistry, 2011
View PDFchevron_right
PAR-5359, a well-balanced PPARα/γ dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo
영준 신
European Journal of Pharmacology, 2008
View PDFchevron_right
Peroxisome proliferator-activated receptors: Targets for the treatment of metabolic illnesses (Review)
oscar enrique gonzalez guerra
Molecular Medicine Reports, 2008
View PDFchevron_right
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
Daniela Schuster
Biochemical Pharmacology, 2014
View PDFchevron_right
Novel Peroxisome Proliferator Activated Receptor–α Agonists
Keith Laderoute
The American Journal of Cardiology, 2007
View PDFchevron_right
Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptor δ agonists as potent anti-obesity agents< i> in vivo
Inho Yang
European journal of …, 2012
View PDFchevron_right
Design and synthesis of novel bis-oximinoalkanoic acids as potent PPARα agonists
Suresh Giri
Bioorganic & Medicinal Chemistry Letters, 2010
View PDFchevron_right
Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptor δ agonists as potent anti-obesity agents in vivo
Harish Holla
European Journal of Medicinal Chemistry, 2012
View PDFchevron_right
Revisiting glitazars: Thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents
suresh giri
Bioorganic & Medicinal Chemistry Letters, 2011
View PDFchevron_right